The technology relates in part to methods for detecting the activity of IL-40 and modified versions thereof. The technology also relates in part to uses of IL-40 for promoting cell differentiation.
01 - Chemical and biological materials for industrial, scientific and agricultural use
09 - Scientific and electric apparatus and instruments
Goods & Services
Chemical preparations for scientific purposes; reagents for
scientific or medical research use; assays and reagents for
use in genetic research; biochemical preparations for
scientific use; biochemical reagents, other than for medical
or veterinary purposes; biological preparation for use in
cell cultures other than for medical or veterinary use;
chemical reagents, other than for medical or veterinary
purposes; buffer solutions for use in analytical chemistry. Laboratory equipment and supplies, namely, test tubes;
laboratory equipment and supplies, namely, centrifuge tubes;
laboratory apparatus and instruments for extracting cells
and cellular components for processing biological material,
sample preparation, extracting cells, isolating cells, and
tissue dissociation, not for medical purposes; disposable
plastic bioreactors for cell culturing.
3.
ANTI-TLR9 AGENTS AND COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME
Compositions and methods for making and using anti-TLR9 agents, for example, monoclonal antibodies, TLR9-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-TLR9 agents, and methods of making and using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
4.
CONTROL CELL POPULATIONS FOR DETECTION OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Provided are systems and methods that may be employed to detect the presence or absence of paroxysmal nocturnal hemoglobinuria (PNH) in a subject that includes a leukocyte including GPI-anchors the leukocyte incubated with one or more blocking agents each independently specific to one or more GPI-anchored proteins, the leukocyte further incubated with a pro-aerolysin or derivative thereof, and optionally a second leukocyte including GPI-anchors not incubated with one or more of the blocking agents. The systems may be used as a positive control in assays detecting the presence or absence of PNH.
Provided are systems and methods that may be employed to detect the presence or absence of paroxysmal nocturnal hemoglobinuria (PNH) in a subject that includes a leukocyte including GPI-anchors the leukocyte incubated with one or more blocking agents each independently specific to one or more GPI-anchored proteins, the leukocyte further incubated with a pro-aerolysin or derivative thereof, and optionally a second leukocyte including GPI-anchors not incubated with one or more of the blocking agents. The systems may be used as a positive control in assays detecting the presence or absence of PNH.
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
6.
ANTI-TLR9 AGENTS AND COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME
Compositions and methods for making and using anti-TLR9 agents, for example, monoclonal antibodies, TLR9-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-TLR9 agents, and methods of making and using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemical preparations for scientific purposes; Reagents for scientific or medical research use; Assays and reagents for use in genetic research; Biochemical preparations for scientific use; Biochemical reagents, other than for medical or veterinary purposes; Biological preparation for use in cell cultures other than for medical or veterinary use; Chemical reagents, other than for medical or veterinary purpose; Buffer solutions for use in analytical chemistry; Biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; Monoclonal antibodies for scientific purposes
8.
ANTI-CD157 ANTIBODIES, ANTIGEN-BINDING FRAGMENTS THEREOF AND COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME
Compositions and methods for making and using anti-CD157 antibodies or antigen-binding fragments thereof, for example, monoclonal antibodies, CD157-binding antibody fragments, and derivatives are described, as are nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-CD157 antibodies or antigen-binding fragments thereof, and methods of making and using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
9.
TAU PHOSPHO (THR217) BINDING ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF
The technology relates in part to antibodies or antigen-binding fragments thereof that bind Tau phosphorylated at threonine 217 (Tau phospho (Thr217)) or a portion thereof, as well as methods, systems and kits for detection of Tau phospho (Thr217). In certain aspects, the technology relates to antibodies or antigen binding fragments thereof for use in determining levels of Tau phospho (Thr217) in a sample containing or suspected of containing Tau phospho (Thr217). In some aspects, the technology relates to antibodies or antigen-binding fragments thereof for use in diagnosing or treating an individual with or suspected of having a disease or disorder associated with Tau phospho (Thr217).
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing online non-downloadable computer software platforms for scientific research; Providing online non-downloadable computer software platforms for use in molecular biology; Providing online non-downloadable computer software platforms for use in biotechnology research; Providing online non-downloadable computer software platforms for cell cycle analysis; Providing online non-downloadable computer software platforms for gene expression profiling; Providing online non-downloadable computer software platforms for cell sorting; Providing online non-downloadable computer software platforms for protein expression; Providing online non-downloadable computer software platforms for importing and analyzing data; Providing online non-downloadable computer software platforms for database management; Providing online non-downloadable computer software platforms for organizing and managing experiments; Providing online non-downloadable computer software platforms for analysis of scientific data and information for use in analyzing cells and particles using reflective and fluorescent properties produced by a flow cytometer apparatus or device; Compiling data for research purposes in the field of medical science and medical consultancy; Providing online non-downloadable virtual assistant software using artificial intelligence (AI) for analyzing scientific research data; Providing online non-downloadable virtual assistant software using artificial intelligence (AI) for analyzing molecular biology data; Providing online non-downloadable virtual assistant software using artificial intelligence (AI) for analyzing biotechnology research data; Providing online non-downloadable virtual assistant software using artificial intelligence (AI) for analyzing and sorting cells; Providing online non-downloadable virtual assistant software using artificial intelligence (AI) for analyzing protein expression data; Providing online non-downloadable virtual assistant software using artificial intelligence (AI) for importing, processing, and analyzing cellular data; Providing online non-downloadable virtual assistant software using artificial intelligence (AI) for managing databases of cellular data; Providing online non-downloadable virtual assistant software using artificial intelligence (AI) for organizing, managing, and tracking scientific experiments; Providing online non-downloadable virtual assistant software using artificial intelligence (AI) for analyzing, processing, and compiling data for scientific research purposes in the field of medical science and medical consultancy
11.
TAU PHOSPHO (THR217) BINDING ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF
The technology relates in part to antibodies or antigen-binding fragments thereof that bind Tau phosphorylated at threonine 217 (Tau phospho (Thr217)) or a portion thereof, as well as methods, systems and kits for detection of Tau phospho (Thr217). In certain aspects, the technology relates to antibodies or antigen binding fragments thereof for use in determining levels of Tau phospho (Thr217) in a sample containing or suspected of containing Tau phospho (Thr217). In some aspects, the technology relates to antibodies or antigen-binding fragments thereof for use in diagnosing or treating an individual with or suspected of having a disease or disorder associated with Tau phospho (Thr217).
Compositions and methods for making and using anti-AXL antibodies or antigen-binding fragments thereof, for example, monoclonal antibodies. AXL-binding antibody fragments, and derivatives are described, as are nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-AXL antibodies or antigen-binding fragments thereof, and methods of making and using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
14.
METHODS AND COMPOSITIONS RELATING TO MOUSE MONOCLONAL ANTI-G4S LINKER ANTIBODIES
Mouse monoclonal antibodies are provided according to aspects of the present disclosure which specifically bind to G4S(n). Mouse monoclonal antibodies which specifically bind to G4S(n) are disclosed which include particular heavy chain variable region complementarity determining regions, light chain variable region complementarity determining regions, and variants thereof. Methods for detecting G4S(n) in a sample according to aspects of the present disclosure include contacting a sample containing or suspected of containing G4S(n) with a mouse monoclonal anti-G4S(n) antibody, under binding conditions; and detecting binding of the anti-G4S(n) antibody thereof with G4S(n). According to aspects of the present disclosure, the sample comprises CAR-T cells, wherein the CAR-T cells comprise an expression construct encoding a G4S(n) adjacent to a chimeric antigen receptor. Immunoassay kits including one or more mouse monoclonal antibodies which specifically bind to G4S(n) of the present disclosure are described herein.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Reagents for scientific and research use; Chemical preparations for scientific purposes; Reagents for scientific or medical research use; Assays and reagents for use in genetic research; Biochemical preparations for scientific use; Biochemical reagents, other than for medical or veterinary purposes; Biological preparation for use in cell cultures other than for medical or veterinary use; Chemical reagents, other than for medical or veterinary purposes; Buffer solutions for use in analytical chemistry; Biological preparations for use in the manufacture of pharmaceuticals; Biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; Antibody reagents used for the detection of antigens in cells and tissue, other than for medical or veterinary purposes; Enzymes for scientific and research purposes; Assays for scientific and research use; Cell culture reagents for scientific and research use; In vitro diagnostic reagents for scientific purposes Antibody reagents used for the detection of antigens in cells and tissue for medical purposes Laboratory equipment and supplies, namely, test tubes; Laboratory equipment and supplies, namely, centrifuge tubes; Laboratory apparatus and instruments for extracting cells and cellular components for processing biological material, sample preparation, extracting cells, isolating cells, and tissue dissociation, not for medical purposes; Disposable plastic bioreactors for cell culturing Providing online non-downloadable computer software platforms for scientific research; Providing online non-downloadable computer software platforms for use in molecular biology; Providing online non-downloadable computer software platforms for cell cycle analysis; Providing online non-downloadable computer software platforms for gene expression profiling; Providing online non-downloadable computer software platforms for cell sorting; Providing online non-downloadable computer software platforms for protein expression; Providing online non-downloadable computer software platforms for importing and analyzing data; Providing online non-downloadable computer software platforms for database management; Providing online non-downloadable computer software platforms for organizing and managing experiments; Providing online non-downloadable computer software platforms for analysis of scientific data and information for use in analyzing cells and particles using reflective and fluorescent properties produced by a flow cytometer apparatus or device; Compiling data for research purposes in the field of medical science and medical consultancy; Providing online non-downloadable computer software platforms for use in biotechnology research; Research and development services in the field of antibodies; Custom design and development of chemical reagents and biochemical assays; Research and development of conjugated antibodies
16.
METHODS AND COMPOSITIONS RELATING TO MOUSE MONOCLONAL ANTI-G4S LINKER ANTIBODIES
Mouse monoclonal antibodies are provided according to aspects of the present disclosure which specifically bind to G4S(n). Mouse monoclonal antibodies which specifically bind to G4S(n) are disclosed which include particular heavy chain variable region complementarity determining regions, light chain variable region complementarity determining regions, and variants thereof. Methods for detecting G4S(n) in a sample according to aspects of the present disclosure include contacting a sample containing or suspected of containing G4S(n) with a mouse monoclonal anti-G4S(n) antibody, under binding conditions; and detecting binding of the anti-G4S(n) antibody thereof with G4S(n). According to aspects of the present disclosure, the sample comprises CAR-T cells, wherein the CAR-T cells comprise an expression construct encoding a G4S(n) adjacent to a chimeric antigen receptor. Immunoassay kits including one or more mouse monoclonal antibodies which specifically bind to G4S(n) of the present disclosure are described herein.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing online non-downloadable computer software
platforms for scientific research; providing online
non-downloadable computer software platforms for use in
molecular biology; providing online non-downloadable
computer software platforms for in biotechnology research;
providing online non-downloadable computer software
platforms for cell cycle analysis; providing online
non-downloadable computer software platforms for gene
expression profiling; providing online non-downloadable
computer software platforms for cell sorting; providing
online non-downloadable computer software platforms for
protein expression; providing online non-downloadable
computer software platforms for import and analyze data;
providing online non-downloadable computer software
platforms for database management; providing online
non-downloadable computer software platforms for organizing
and managing experiments; providing online non-downloadable
computer software platforms for analysis of scientific data
and information for use in analyzing cells and particles
using reflective and fluorescent properties produced by a
flow cytometer apparatus or device.
18.
COMPOSITIONS FOR USE WITH MULTIPLE FLUOROPHORES AND METHODS OF USING
Improved compositions and methods of using the compositions in detecting the presence or absence of an analyte are disclosed. These compositions may provide improved signal with fewer false double positive populations observed, by dramatically reducing stacking of polymer dyes and allowing the use of multiple polymer dyes in a single tube thereby improving methods of using such compositions for fluorescent analyses.
Improved compositions and methods of using the compositions in detecting the presence or absence of an analyte are disclosed. These compositions may provide improved signal with fewer false double positive populations observed, by dramatically reducing stacking of polymer dyes and allowing the use of multiple polymer dyes in a single tube thereby improving methods of using such compositions for fluorescent analyses.
Improved compositions and methods of using the compositions in detecting the presence or absence of an analyte are disclosed. These compositions may provide improved signal with reduced background and in some aspects fewer false double positive populations observed, by dramatically reducing stacking of polymer dyes and allowing the use of multiple polymer dyes in a single tube thereby improving methods of using such compositions for fluorescent analyses.
Improved compositions and methods of using the compositions in detecting the presence or absence of an analyte are disclosed. These compositions may provide improved signal with reduced background and in some aspects fewer false double positive populations observed, by dramatically reducing stacking of polymer dyes and allowing the use of multiple polymer dyes in a single tube thereby improving methods of using such compositions for fluorescent analyses.
B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
The technology relates in part to antibodies or antigen-binding fragments thereof that bind one or more members of the KIR family of proteins (e.g., KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL2, and/or KIR3DL3) or portions thereof, as well as methods, systems and kits for detection of KIR. In certain aspects, the technology relates to antibodies or antigen binding fragments thereof for use in determining levels of KIR in a sample containing or suspected of containing KIR. In some aspects, the technology relates to antibodies or antigen-binding fragments thereof for use in diagnosing or treating an individual with or suspected of having a disease or disorder associated with KIR.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
01 - Chemical and biological materials for industrial, scientific and agricultural use
09 - Scientific and electric apparatus and instruments
Goods & Services
Chemical preparations for scientific purposes; Reagents for scientific or medical research use; Assays and reagents for use in genetic research; Biochemical preparations for scientific use; Biochemical reagents, other than for medical or veterinary purposes; Biological preparation for use in cell cultures other than for medical or veterinary use; Chemical reagents, other than for medical or veterinary purposes; Buffer solutions for use in analytical chemistry Laboratory equipment and supplies, namely, test tubes; Laboratory equipment and supplies, namely, centrifuge tubes; Laboratory apparatus and instruments for extracting cells and cellular components for processing biological material, sample preparation, extracting cells, isolating cells, and tissue dissociation, not for medical purposes; Disposable plastic bioreactors for cell culturing
24.
CHI3L1 BINDING ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF
The technology relates in part to antibodies or antigen-binding fragments thereof that bind CHI3L1 or a portion thereof, as well as methods, systems and kits for detection of CHI3L1. In certain aspects, the technology relates to antibodies or antigen binding fragments thereof for use in determining levels of CHI3L1 in a sample containing or suspected of containing CHI3L1. In some aspects, the technology relates to antibodies or antigen-binding fragments thereof for use in diagnosing or treating an individual with or suspected of having a disease or disorder associated with CHI3L1.
The technology relates in part to antibodies or antigen-binding fragments thereof that bind CHI3L1 or a portion thereof, as well as methods, systems and kits for detection of CHI3L1. In certain aspects, the technology relates to antibodies or antigen binding fragments thereof for use in determining levels of CHI3L1 in a sample containing or suspected of containing CHI3L1. In some aspects, the technology relates to antibodies or antigen-binding fragments thereof for use in diagnosing or treating an individual with or suspected of having a disease or disorder associated with CHI3L1.
The present disclosure provides fluorescent polyindenofluorene polymers or macromers with unique optical properties that are stable. The polymeric fluorophores are useful in various bioassays formats. The inventive polymers are useful in assays relying on fluorescence resonance energy transfer (FRET) mechanisms where two fluorophores are used.
C08G 61/10 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aromatic carbon atoms, e.g. polyphenylenes
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Providing online non-downloadable computer software platforms for scientific research; providing online non-downloadable computer software platforms for use in molecular biology; providing online non-downloadable computer software platforms for in biotechnology research; providing online non-downloadable computer software platforms for cell cycle analysis; providing online non-downloadable computer software platforms for gene expression profiling; providing online non-downloadable computer software platforms for cell sorting; providing online non-downloadable computer software platforms for protein expression; providing online non-downloadable computer software platforms for import and analyze data; providing online non-downloadable computer software platforms for database management; providing online non-downloadable computer software platforms for organizing and managing experiments; providing online non-downloadable computer software platforms for analysis of scientific data and information for use in analyzing cells and particles using reflective and fluorescent properties produced by a flow cytometer apparatus or device.
28.
VISUALIZING INTRA-CELL CO-EXPRESSION OF CELLULAR CONSTITUENTS USING DIMENSIONALITY REDUCTION THAT IS WEIGHTED BY CELL TYPE
A facility for analyzing a sample of cells is described. The facility accesses an emphasis weight specifying a degree to which cell type is to be emphasized relative to cell constituent expression levels in determining visualization coordinates for each cell of the sample. The facility generates a cell matrix comprising a grid of values in which each row represents a cell of the sample, in which a first group of the columns correspond to constituent expression levels detected for the cell, and a second group of the columns correspond to a representation established for the cell's cell type, the values in the first group of the columns being weighted against the values in the second group of the columns in accordance with the accessed emphasis weight. The facility performs dimensionality reduction on the rows of the generated cell matrix to obtain visualization coordinates for each cell of the sample.
A facility for analyzing a sample of cells is described. The facility accesses an emphasis weight specifying a degree to which cell type is to be emphasized relative to cell constituent expression levels in determining visualization coordinates for each cell of the sample. The facility generates a cell matrix comprising a grid of values in which each row represents a cell of the sample, in which a first group of the columns correspond to constituent expression levels detected for the cell, and a second group of the columns correspond to a representation established for the cell's cell type, the values in the first group of the columns being weighted against the values in the second group of the columns in accordance with the accessed emphasis weight. The facility performs dimensionality reduction on the rows of the generated cell matrix to obtain visualization coordinates for each cell of the sample.
This disclosure relates to a compound comprising A and B; where one or more A groups are linked to one or more B groups by an electron conducting conjugated bond configured to delocalize one or more electrons between A and B; a method of detecting the presence or absence of an analyte in a sample or an organism, the method comprising: contacting a sample with a composition comprising a dendrimer structure and a compound as provided herein; exposing the sample to light of a wavelength of light that excites the compound of the composition; and detecting the presence or absence of light emitted by the composition; and a method of forming a dendrimer composition comprising: contacting a dendrimer with a compound comprising a compound as provided herein, thereby forming a dendrimer composition; and contacting the dendrimer composition with a probe under conditions where the dendrimer composition binds to the probe.
Provided herein are antibodies, including antigen-binding fragments thereof, that bind all or a portion thereof of GPC4, compositions containing such antibodies or antigen-binding fragments thereof, combinations of such antibodies or antigen-binding fragments thereof and methods of use. In particular embodiments, the antibodies or antigen-binding fragments thereof are used in methods of detecting the presence of GPC4 through imaging, including molecular, medical and diagnostic imaging.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
32.
COMPOSITIONS AND METHODS FOR ENHANCED SAMPLE MULTIPLEXING
Provided herein are compositions, methods and systems that allow for detection of samples via compositions that bind ubiquitous ligands or targets, to improve the capability of multi-sample utilization in single cell sequencing.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing online non-downloadable computer software platforms for scientific research; Providing online non-downloadable computer software platforms for use in molecular biology; Providing online non-downloadable computer software platforms for use in biotechnology research; Providing online non-downloadable computer software platforms for cell cycle analysis; Providing online non-downloadable computer software platforms for gene expression profiling; Providing online non-downloadable computer software platforms for cell sorting; Providing online non-downloadable computer software platforms for protein expression; Providing online non-downloadable computer software platforms for importing and analyzing data; Providing online non-downloadable computer software platforms for database management; Providing online non-downloadable computer software platforms for organizing and managing experiments; Providing online non-downloadable computer software platforms for analysis of scientific data and information for use in analyzing cells and particles using reflective and fluorescent properties produced by a flow cytometer apparatus or device; Compiling data for research purposes in the field of medical science and medical consultancy
34.
CD28 BINDING ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
35.
CEACAM6 BINDING ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
Provided herein are antibodies, including antigen-binding fragments thereof, that bind all or a portion thereof of CEACAM6, compositions containing such antibodies or antigen-binding fragments thereof, combinations of such antibodies or antigen-binding fragments thereof and methods of use. In particular embodiments, the antibodies or antigen-binding fragments thereof are used in methods of detecting the presence of CEACAM6 through imaging, including molecular, medical and diagnostic imaging.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention provides fluorescent polyfluorene polymers or macromers with unique optical properties that are stable. The polymeric fluorophores are useful in various bioassays formats. The inventive polymers are useful in assays relying on fluorescence resonance energy transfer (FRET) mechanisms where two fluorophores are used.
C07C 211/60 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton containing a ring other than a six-membered aromatic ring forming part of at least one of the condensed ring systems
C07C 237/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
C07D 211/18 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
C07D 235/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
C07D 311/96 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
C08G 81/00 - Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
C09B 57/00 - Other synthetic dyes of known constitution
Compositions and methods for making and using anti-CCR8 antibodies, antigen-binding fragments thereof, or agents, for example, monoclonal antibodies, CCR8-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-CCR8 antibodies, antigen-binding fragments thereof, or agents, and methods of making and using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to the phosphatidylserine (PS) binding compound derivative and the fusion of PS binding compound with an arm compound. The present invention describes the methods of producing and using PS binding compound derivative and the fusion of PS binding compound with an arm compound by providing the functional group to couple with functional group containing fluorophore for multicolor flow cytometry and multiplex imaging; to conjugate with magnetic particle for depleting the PS positive cells; to couple with oligo comprising PCR handle sequence, and unique DNA barcode for PS positive cells and capture sequence for discriminating positive cells from live cells in Single-cell RNA sequencing.
The present invention relates to the phosphatidylserine (PS) binding compound derivative and the fusion of PS binding compound with an arm compound. The present invention describes the methods of producing and using PS binding compound derivative and the fusion of PS binding compound with an arm compound by providing the functional group to couple with functional group containing fluorophore for multicolor flow cytometry and multiplex imaging; to conjugate with magnetic particle for depleting the PS positive cells; to couple with oligo comprising PCR handle sequence, and unique DNA barcode for PS positive cells and capture sequence for discriminating positive cells from live cells in Single-cell RNA sequencing.
A data structure relating to a sample of cells is described. The data structure includes first data elements each representing one of a number of first-degree nodes. Each of the first-degree nodes corresponds to a different one of a number of cellular constituents. Each first data element includes a quantitative indication of the portion of cells of the sample in which the constituent has positive expression. The data structure also includes second data elements each representing one of a number of greater-than-first-degree nodes, which each correspond to a different subset of the constituents of size two or more. Each second data element includes a quantitative indication of the portion of cells of the sample in which the subset of constituents all have positive expression. The contents of the data structure are usable to generate a visual co-expression graph characterizing the sample.
A data structure relating to a sample of cells is described. The data structure includes first data elements each representing one of a number of first-degree nodes. Each of the first-degree nodes corresponds to a different one of a number of cellular constituents. Each first data element includes a quantitative indication of the portion of cells of the sample in which the constituent has positive expression. The data structure also includes second data elements each representing one of a number of greater-than-first-degree nodes, which each correspond to a different subset of the constituents of size two or more. Each second data element includes a quantitative indication of the portion of cells of the sample in which the subset of constituents all have positive expression. The contents of the data structure are usable to generate a visual co-expression graph characterizing the sample.
The present invention relates to a phosphatidylserine (PS) binding agents comprising one or more C-domains of a milk fat globule-EGF factor 8 (MFG-E8) protein, and methods of making and using the same.
Compositions and methods for making and using anti-AXL antibodies or antigen-binding fragments thereof, for example, monoclonal antibodies, AXL-binding antibody fragments, and derivatives are described, as are nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-AXL antibodies or antigen-binding fragments thereof, and methods of making and using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
44.
ANTI-CD157 ANTIBODIES, ANTIGEN-BINDING FRAGMENTS THEREOF AND COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME
Compositions and methods for making and using anti-CD157 antibodies or antigen-binding fragments thereof, for example, monoclonal antibodies, CD157-binding antibody fragments, and derivatives are described, as are nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-CD157 antibodies or antigen-binding fragments thereof, and methods of making and using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
45.
COMPOSITIONS AND METHODS FOR PERFORMING MAGNETIBUOYANT SEPARATIONS
The methods of the invention employ targeted magnetic particles, preferably targeted nanomagnetic particles, and targeted buoyant particles such as buoyant microparticles and microbubbles. Among the benefits of the invention is the ability to combine targeted magnetic particles with differentially targeted buoyant particles to achieve separation of two or more specifically cell targeted populations during the same work flow.
B01J 20/06 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group
B01J 20/10 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
B01J 20/24 - Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
B03C 1/015 - Pretreatment specially adapted for magnetic separation by chemical treatment imparting magnetic properties to the material to be separated, e.g. roasting, reduction, oxidation
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
The disclosure relates in part to methods and compositions for detecting targets in a sample. Such methods and compositions can be useful for laboratory, research, and diagnostic purposes.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
Provided herein are compositions, methods and systems that allow for detection of samples via compositions that bind ubiquitous ligands or targets, to improve the capability of multi-sample utilization in single cell sequencing.
Processes and compositions are described for preparing new, colloidally stable, coated nanomagnetic particles useful for both in-vitro and in-vivo biomedical applications, including cell targeting and capturing cells, microorganisms, and cellular organelles or entities such as exosomes. These nanomagnetic particles can also be used as imaging contrast agents due to their small size and high magnetic moment. The nanomagnetic particles include a series of sequentially added, stabilizing surface coatings rendered onto nano-sized magnetic crystal clusters (e.g., magnetite particles) to impart colloidal stability in complex biological samples with minimal leaching of the coating materials, high binding capacity, and low non-specific binding. Another benefit of this invention is the ability to utilize both external and internal magnetic field-generating separation devices to effect separation of the magnetic nanoparticles.
The present disclosure provides fluorescent polyindenofluorene polymers or macromers with unique optical properties that are stable. The polymeric fluorophores are useful in various bioassays formats. The inventive polymers are useful in assays relying on fluorescence resonance energy transfer (FRET) mechanisms where two fluorophores are used.
C08G 61/10 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aromatic carbon atoms, e.g. polyphenylenes
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
52.
Anti-TLR7 agents and compositions and methods for making and using the same
Compositions and methods for making and using anti-TLR7 agents, for example, monoclonal antibodies, TLR7-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-TLR7 agents, and methods of making and using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
53.
ANTI-CCR8 ANTIBODIES, ANTIGEN-BINDING FRAGMENTS THEREOF, AND AGENTS AND COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME
Compositions and methods for making and using anti-CCR8 antibodies, antigen-binding fragments thereof, or agents, for example, monoclonal antibodies, CCR8-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-CCR8 antibodies, antigen-binding fragments thereof, or agents, and methods of making and using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
The present invention relates to a phosphatidylserine (PS) binding agents comprising one or more C-domains of a milk fat globule-EGF factor 8 (MFG-E8) protein, and methods of making and using the same.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Compositions and methods for making and using anti-CD117 agents, for example, monoclonal antibodies, CD117-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-CD117 agents, and methods of making and using the same.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Compositions and methods for making and using anti-SARS-CoV-2 Spike glycoprotein S1 agents, for example, monoclonal antibodies, SARS-CoV-2 Spike glycoprotein S1-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-SARS-CoV-2 Spike glycoprotein S1 agents, and methods of making and using the same.
Compositions and methods for making and using anti-NKG2C agents, for example, monoclonal antibodies, NKG2C-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-NKG2C agents, and methods of making and using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
59.
ANTI-NKG2A AGENTS AND COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME
Compositions and methods for making and using anti-NKG2A agents, for example, monoclonal antibodies, NKG2A-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-NKG2A agents, and methods of making and using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
60.
Uses of IL-40 and methods for detecting IL-40 activity
The technology relates in part to methods for detecting the activity of IL-40 and modified versions thereof. The technology also relates in part to uses of IL-40 for promoting cell differentiation.
The present invention provides fluorescent polyfluorene polymers or macromers with unique optical properties that are stable. The polymeric fluorophores are useful in various bioassays formats. The inventive polymers are useful in assays relying on fluorescence resonance energy transfer (FRET) mechanisms where two fluorophores are used.
C07C 211/60 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton containing a ring other than a six-membered aromatic ring forming part of at least one of the condensed ring systems
C07C 237/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
C07D 211/18 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
C07D 235/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
C07D 311/96 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
C08G 81/00 - Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
C09B 57/00 - Other synthetic dyes of known constitution
The disclosure relates in part to methods and compositions for detecting targets in a sample. Such methods and compositions can be useful for laboratory, research, and diagnostic purposes.
Compositions and methods for making and using anti-TLR7 agents, for example, monoclonal antibodies, TLR7-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-TLR7 agents, and methods of making and using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
65.
Anti-TLR9 agents and compositions and methods for making and using the same
Compositions and methods for making and using anti-TLR9 agents, for example, monoclonal antibodies, TLR9-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-TLR9 agents, and methods of making and using the same.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
66.
Anti-tetraspanin 33 agents and compositions and methods for making and using the same
Compositions and methods for making and using anti-TSPAN33 agents, for example, monoclonal antibodies, TSPAN33-binding antibody fragments, and derivatives, are described.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
67.
USES OF IL-40 AND METHODS FOR DETECTING IL-40 ACTIVITY
The technology relates in part to methods for detecting the activity of IL-40 and modified versions thereof. The technology also relates in part to uses of IL-40 for promoting cell differentiation.
The present disclosure provides fluorescent polyindenofluorene polymers or macromers with unique optical properties that are stable. The polymeric fluorophores are useful in various bioassays formats. The inventive polymers are useful in assays relying on fluorescence resonance energy transfer (FRET) mechanisms where two fluorophores are used.
C08G 61/10 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aromatic carbon atoms, e.g. polyphenylenes
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
Processes and compositions are described for preparing new, colloidally stable, coated nanomagnetic particles useful for both in-vitro and in-vivo biomedical applications, including cell targeting and capturing cells, microorganisms, and cellular organelles or entities such as exosomes. These nanomagnetic particles can also be used as imaging contrast agents due to their small size and high magnetic moment. The nanomagnetic particles include a series of sequentially added, stabilizing surface coatings rendered onto nano-sized magnetic crystal clusters (e.g., magnetite particles) to impart colloidal stability in complex biological samples with minimal leaching of the coating materials, high binding capacity, and low non-specific binding. Another benefit of this invention is the ability to utilize both external and internal magnetic field-generating separation devices to effect separation of the magnetic nanoparticles.
Compositions and methods for making and using anti-TLR9 agents, for example, monoclonal antibodies, TLR9-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-TLR9 agents, and methods of making and using the same.
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Compositions and methods for making and using anti-TSPAN33 agents, for example, monoclonal antibodies, TSPAN33-binding antibody fragments, and derivatives, are described.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides fluorescent polyfluorene polymers or macromers with unique optical properties that are stable. The polymeric fluorophores are useful in various bioassays formats. The inventive polymers are useful in assays relying on fluorescence resonance energy transfer (FRET) mechanisms where two fluorophores are used.
C09B 69/10 - Polymeric dyesReaction products of dyes with monomers or with macromolecular compounds
C08G 81/00 - Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
C07C 25/22 - Polycyclic aromatic halogenated hydrocarbons with condensed rings
C07C 237/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
C07D 235/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
C07D 311/96 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
C07D 211/18 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
C09B 57/00 - Other synthetic dyes of known constitution
C07C 211/60 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton containing a ring other than a six-membered aromatic ring forming part of at least one of the condensed ring systems
74.
Compositions and methods for performing magnetibuoyant separations
The methods of the invention employ targeted magnetic particles, preferably targeted nanomagnetic particles, and targeted buoyant particles such as buoyant microparticles and microbubbles. Among the benefits of the invention is the ability to combine targeted magnetic particles with differentially targeted buoyant particles to achieve separation of two or more specifically cell targeted populations during the same work flow.
B01J 20/06 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group
B01J 20/10 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
B01J 20/24 - Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
B03C 1/015 - Pretreatment specially adapted for magnetic separation by chemical treatment imparting magnetic properties to the material to be separated, e.g. roasting, reduction, oxidation
The present disclosure provides fluorescent polyindenofluorene polymers or macromers with unique optical properties that are stable. The polymeric fluorophores are useful in various bioassays formats. The inventive polymers are useful in assays relying on fluorescence resonance energy transfer (FRET) mechanisms where two fluorophores are used..
The present invention provides fluorescent polyfluorene polymers or macromers with unique optical properties that are stable. The polymeric fluorophores are useful in various bioassays formats. The inventive polymers are useful in assays relying on fluorescence resonance energy transfer (FRET) mechanisms where two fluorophores are used.
C07D 311/96 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
C07D 235/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
C07C 211/60 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton containing a ring other than a six-membered aromatic ring forming part of at least one of the condensed ring systems
C07C 237/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
C07D 211/18 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
C08G 81/00 - Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
C07C 25/22 - Polycyclic aromatic halogenated hydrocarbons with condensed rings
77.
COMPOSITIONS AND METHODS FOR PERFORMING MAGNETIBUOYANT SEPARATIONS
Processes and compositions are provided for performing magnetibuoyant separations of different biomolecules (e.g., cells, organelles, etc.) in a biological sample, as well as compositions and kits for performing such methods. Compositions containing the separated biomolecules, and methods for using the same for in-vitro and in-vivo biomedical applications, are also provided. The magnetibuoyant methods of the invention employ targeted magnetic particles, preferably targeted nanomagnetic particles, and targeted buoyant particles such as buoyant microparticles and microbubbles. Among the benefits of the invention is the ability to combine targeted magnetic particles with differentially targeted buoyant particles to achieve separation of two or more specifically cell targeted populations during the same work flow.
Processes and compositions are described for preparing new, colloidally stable, coated nanomagnetic particles useful for both in-vitro and in-vivo biomedical applications, including cell targeting and capturing cells, microorganisms, and cellular organelles or entities such as exosomes. These nanomagnetic particles can also be used as imaging contrast agents due to their small size and high magnetic moment. The nanomagnetic particles include a series of sequentially added, stabilizing surface coatings rendered onto nano-sized magnetic crystal clusters (e.g., magnetite particles) to impart colloidal stability in complex biological samples with minimal leaching of the coating materials, high binding capacity, and low non-specific binding. Another benefit of this invention is the ability to utilize both external and internal magnetic field-generating separation devices to effect separation of the magnetic nanoparticles.
B01D 21/00 - Separation of suspended solid particles from liquids by sedimentation
C04B 35/00 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
Processes and compositions are described for preparing new, colloidally stable, coated nanomagnetic particles useful for both in-vitro and in-vivo biomedical applications, including cell targeting and capturing cells, microorganisms, and cellular organelles or entities such as exosomes. These nanomagnetic particles can also be used as imaging contrast agents due to their small size and high magnetic moment. The nanomagnetic particles include a series of sequentially added, stabilizing surface coatings rendered onto nano-sized magnetic crystal clusters (e.g., magnetite particles) to impart colloidal stability in complex biological samples with minimal leaching of the coating materials, high binding capacity, and low non-specific binding. Another benefit of this invention is the ability to utilize both external and internal magnetic field-generating separation devices to effect separation of the magnetic nanoparticles.
C04B 35/00 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products
C09D 5/23 - Magnetisable or magnetic paints or lacquers
Processes and compositions are described for preparing new, colloidally stable, coated nanomagnetic particles useful for both in-vitro and in-vivo biomedical applications, including cell targeting and capturing cells, microorganisms, and cellular organelles or entities such as exosomes. These nanomagnetic particles can also be used as imaging contrast agents due to their small size and high magnetic moment. The nanomagnetic particles include a series of sequentially added, stabilizing surface coatings rendered onto nano-sized magnetic crystal clusters (e.g., magnetite particles) to impart colloidal stability in complex biological samples with minimal leaching of the coating materials, high binding capacity, and low non-specific binding. Another benefit of this invention is the ability to utilize both external and internal magnetic field-generating separation devices to effect separation of the magnetic nanoparticles.
01 - Chemical and biological materials for industrial, scientific and agricultural use
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemicals used in industry, science and photography; reagents for scientific or research use; chemical preparations for analysis in laboratories; biochemical catalysts; biological preparations and substances. Scientific and technological services and research and design relating thereto; biological research services; industrial analysis and research services.
